Edgewise Therapeutics
Xiaohong Shen serves as the Director of Pharmaceutical Development & Technology Transfer at Edgewise Therapeutics since May 2024, bringing extensive experience in pharmaceutical development. Prior roles include Senior Director of Pharmaceutical Development & Technology Transfer at TG Therapeutics, Inc., and Project Lead/Senior Scientist at Ferring Pharmaceuticals, where notable work involved implementing QbD principles and developing abuse-deterrent technologies for opioids. Xiaohong's early career featured positions at Purdue Pharma L.P. and Novartis, focusing on formulation and process optimization for both early and late phase projects. Additional experience encompasses management roles in production and quality control at Nanjing Chemical Industrial Company, including the establishment and oversight of production and quality analysis processes. Education was completed at the University of Iowa.
This person is not in any teams
This person is not in any offices
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.